Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
876.7 INR | -0.76% | +3.94% | +35.03% |
Apr. 09 | Strides Pharma Science Gets US FDA Nod for Fluoxetine Tabs | MT |
Jan. 30 | Transcript : Strides Pharma Science Limited, Q3 2024 Earnings Call, Jan 30, 2024 |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+35.03% | 966M | B | ||
+19.62% | 43.34B | B- | ||
+20.44% | 21.96B | B+ | ||
+10.86% | 14.09B | - | ||
+13.07% | 13.64B | B+ | ||
+37.46% | 11.43B | B | ||
-8.59% | 6.86B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+8.46% | 5.22B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- STAR Stock
- Ratings Strides Pharma Science Limited